Ultivue utilizes its proprietary InSituPlex® technology for high-precision spatial immunoprofiling, enabling simultaneous detection of multiple biomarkers with 30x greater signal-to-noise ratios compared to conventional methods. This approach significantly reduces custom biomarker development timelines from months to weeks, facilitating rapid hypothesis verification in translational research.
Funding
$3.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional methods for spatial immunoprofiling of tissue samples often suffer from low signal-to-noise ratios, limiting the ability to accurately detect and quantify multiple biomarkers simultaneously. Developing custom biomarker panels using conventional techniques is a lengthy process, hindering rapid hypothesis verification in translational research.
Solution
Ultivue offers spatial immunoprofiling solutions based on its proprietary InSituPlex® technology, enabling high-precision, multiplexed biomarker detection in tissue samples. InSituPlex® assays utilize direct labeling and visualization of antigen target sites, providing enhanced sensitivity and specificity with 30x greater signal-to-noise ratios compared to conventional immunofluorescence assays. Pre-validated OmniVUE™ panels offer flexibility in panel design, allowing researchers to select combinations of biomarkers from a core menu. The modularity and simplicity of InSituPlex® technology significantly reduces custom marker and panel development timelines, accelerating translational research. The STARVUE™ image data science platform employs AI-enhanced models for tissue and cell segmentation, biomarker classification, and spatial phenotyping at scale.
Target Audience
The primary audience includes translational researchers and clinical researchers who require precise and quantitative spatial immunoprofiling of tissue samples for biomarker discovery and validation.
Features
- InSituPlex® (ISP) assays for direct labeling and visualization of antigen target sites
- 30x greater signal-to-noise ratios compared to conventional immunofluorescence assays
- OmniVUE™ pre-validated biomarker panels for flexible panel design
- Custom biomarker and panel development with reduced timelines (6-8 weeks)
- Compatibility with automated staining systems like BOND RX by Leica Biosystems
- STARVUE™ image data science platform with AI-enhanced tissue and cell segmentation
- Deep-learning based models for biomarker classification and spatial phenotyping
- UltiStacker.AI™ for co-registration of multiple rounds of immunofluorescent and brightfield images
- UltiAnalyzer.AI™ for advanced cellular phenotyping through whole-slide image analysis